A comparison of regorafenib and fruquintinib for metastatic colorectal cancer: a systematic review and network meta-analysis
- 101 Downloads
The optimal treatment in the third-line and later-line setting for metastatic colorectal cancer (mCRC) has not been established. As reported, regorafenib and fruquintinib have shown to be superior to placebo in mCRC. However, no direct clinical comparison of regorafenib and fruquintinib has been conducted; we performed a systematic review and network meta-analysis to compare the efficacy and safety of regorafenib and fruquintinib.
PubMed, Embase, and the Cochrane Library were systematically searched and randomized-controlled trials (RCTs) assessing the effect and safety of regorafenib or fruquintinib versus placebo for patients with mCRC were included. Two investigators independently searched articles, extracted data, and assessed the quality of included studies. After that, we performed pairwise direct meta-analyses (regorafenib vs. placebo and fruquintinib vs. placebo) and indirect comparison (regorafenib vs. fruquintinib) using network meta-analyses methods.
Three RCTs involving 1380 patients were included in the meta-analysis. In the direct meta-analysis, regorafenib and fruquintinib both showed survival benefits when compared with placebo. For the indirect comparison, fruquintinib shows no significant difference in OS compared to regorafenib (HR 0.97; 95% CI 0.64–1.46). Regarding PFS, there was a tendency that fruquintinib was superior to regorafenib (HR 0.65; 95% CI 0.39–1.08); however, there was no statistic difference. For the safety analysis, in indirect comparison, fruquintinib showed significant difference in all-grade toxicity compared to regorafenib (OR 0.73; 95% CI 0.65–0.82), especially in subgroup of proteinuria (OR 0.31; 95% CI 0.11–0.86). For the grade 3–5 toxicity, fruquintinib showed no significant difference when compared with regorafenib (OR 0.92; 95% CI 0.64–1.32).
Based on efficacy and safety, there was a tendency that fruquintinib was superior to regorafenib, as a whole, regorafenib and fruquintinib demonstrated similar clinical benefit for patients with refractory mCRC. It seems that fruquintinib has less toxic in all-grade toxicity when compared with regorafenib.
KeywordsComparative effectiveness Network meta-analysis Metastatic colorectal cancer Regorafenib Fruquintinib
This study was supported by the National Natural Science Foundation of China (Grant numbers 81803569).
Compliance with ethical standards
Conflict of interest
All the authors declare that they have no conflict of interest.
This article does not contain any studies with human participants or animals performed by any of the authors.
- Bekaii-Saab TS, Ou FS, Ciombor KK et al (2016) Regorafenib dose optimization study (ReDOS): a phase II randomized study of lower starting dose regorafenib compared to standard dose regorafenib in patients with refractory metastatic colorectal cancer (mCRC). J Clin Oncol. https://doi.org/10.1200/JCO.2016.34.15_suppl.TPS3630 Google Scholar
- Bozzarelli S, Rimassa L, Giordano L, et al (2016) Regorafenib in patients with refractory metastatic pancreatic cancer. An open-label phase II study (RESOUND). Annals of oncology. Conference: 41st european society for medical oncology congress, ESMO 2016. Denmark. Conference start: 20161007. Conference end: 20161011Google Scholar
- Cao J, Zhang J, Peng W et al (2016) A Phase I study of safety and pharmacokinetics of fruquintinib, a novel selective inhibitor of vascular endothelial growth factor receptor-1, -2, and -3 tyrosine kinases in Chinese patients with advanced solid tumors. Cancer Chemother Pharmacol 78:259–269CrossRefGoogle Scholar
- Ferlay J, Colombet M, Soerjomataram I et al (2019) Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer 144:1941–1953Google Scholar
- Hofheinz RD, Giardello F, Seitz JF et al (2016) CONSIGN-an open-label phase-3B-study of regorafenib in patients with metastatic colorectal cancer (mCRC) who failed standard therapy. Oncol Res Treat 39:10Google Scholar
- Jprn U (2013) Randomized phase II Study of regorafenib followed by cetuximab versus Reverse Sequence for wild-type KRAS metastatic colorectal cancer previously treated with Fluoropyrimidine, Oxaliplatin, and Irinotecan (REVERECE). http://www.who.int/trialsearch/trial2.aspx? Trialid = jprn-umin000011294. Accessed Apr 2019
- US Food and Drug Administration (2012) FDA approves regorafenib (Stivarga) for metastatic colorectal cancer. Oncol (Williston Park) 26:896Google Scholar